News stories about Blueprint Medicines (NASDAQ:BPMC) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Blueprint Medicines earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.8117586131366 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
Blueprint Medicines (NASDAQ:BPMC) traded up $0.79 during mid-day trading on Friday, hitting $79.24. 158,155 shares of the company were exchanged, compared to its average volume of 417,304. Blueprint Medicines has a 1 year low of $30.98 and a 1 year high of $92.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. The stock has a market capitalization of $3,364.15, a price-to-earnings ratio of -23.24 and a beta of 1.29.
Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). The company had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.62) earnings per share. research analysts anticipate that Blueprint Medicines will post -3.75 EPS for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. JMP Securities increased their price objective on shares of Blueprint Medicines from $88.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 11th. Morgan Stanley increased their price objective on shares of Blueprint Medicines from $45.00 to $78.00 and gave the company an “overweight” rating in a report on Monday, October 23rd. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Tuesday, October 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $80.00 price objective (up from $66.00) on shares of Blueprint Medicines in a report on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.10.
In related news, insider Marion Dorsch sold 18,334 shares of Blueprint Medicines stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $65.45, for a total value of $1,199,960.30. Following the completion of the sale, the insider now directly owns 18,334 shares in the company, valued at $1,199,960.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anthony L. Boral sold 5,000 shares of Blueprint Medicines stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $70.40, for a total value of $352,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 58,334 shares of company stock valued at $3,978,160. 3.40% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Blueprint Medicines (BPMC) Receives Media Impact Rating of 0.17” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/blueprint-medicines-bpmc-receiving-somewhat-favorable-media-coverage-study-shows.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.